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Disease Activity, Physical Function, and Radiographic
Progression After Longterm Therapy with
Adalimumab Plus Methotrexate: 5-Year Results
of PREMIER
DÉSIRÉE van der HEIJDE, FERDINAND C. BREEDVELD, ARTHUR KAVANAUGH, EDWARD C. KEYSTONE,
ROBERT LANDEWÉ, KAUSHIK PATRA, and AILEEN L. PANGAN
ABSTRACT. Objective. To evaluate the efficacy and safety of initial combination treatment with adalimumab
(ADA) and methotrexate (MTX) versus monotherapy with ADA or MTX during an open-label
extension of PREMIER.
Methods. Patients with early rheumatoid arthritis (RA) received blinded ADA plus MTX, ADA
alone, or MTX alone for 2 years in PREMIER. At Year 2, patients could enroll in an open-label
extension and receive ADA monotherapy; MTX could be added at the investigator’s discretion.
Longterm efficacy results are presented as observed data.
Results. In the open-label period, 497 of the original 799 randomized patients had ≥ 1 dose of ADA
(by original randomization: ADA plus MTX, n = 183; ADA, n = 159; MTX, n = 155). In the com-
pleters cohort [patients with available Year-5 ACR responses and modified total Sharp scores
(mTSS)], the Year-5 mean change from baseline in mTSS for the ADA+MTX arm (n = 124) was
2.9, compared with 8.7 and 9.7 in the ADA (n = 115) and MTX (n = 115) arms. Comprehensive dis-
ease remission, defined as the combination of DAS28 remission, normal function (Health
Assessment Questionnaire ≤ 0.5), and radiographic nonprogression (∆mTSS ≤ 0.5), was achieved
by more patients in the initial ADA+MTX arm (35%) than in the ADA (13%) or MTX (14%) arms.
Conclusion. Initial combination treatment with ADA plus MTX, followed by open-label ADA, led
to better longterm clinical, functional, and radiographic outcomes than either initial ADA or MTX
monotherapy during 5 years of treatment. (First Release Oct 1 2010; J Rheumatol 2010;37:2237–46;
doi:10.3899/jrheum.100208)
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In patients with rheumatoid arthritis (RA) and aggressive
disease, joint erosions may occur as early as within 6
months of disease onset. The progression of damage then
occurs rapidly, especially during the first 2 years1,2. The
optimal management approach for such patients takes into
consideration the appropriate type and timing of therapy. It
has been shown that early identification and treatment of
RA can reduce disease progression and loss of function3.
However, few studies have prospectively evaluated the
influence of early RA treatment on prevention of both radio-
graphic damage and clinical disease progression, especially
over the long term4.
Studies have shown that a combination of a tumor necro-
sis factor (TNF) antagonist plus methotrexate (MTX) is
superior to MTX alone in significantly improving clinical
signs and symptoms of RA and inhibiting radiographic pro-
gression5,6,7. TNF antagonist treatment has also been shown
to significantly improve physical functioning and health-
related quality of life8, as well as employment outcomes
such as job loss9, and work productivity10.
PREMIER was a 2-year, randomized, double-blind study
of patients with early RA. The design included 3 treatment
arms representing 3 therapeutic options available to rheuma-
tologists for treating patients with early RA: a combination
of an anti-TNF agent plus MTX [adalimumab (ADA) plus
MTX], monotherapy with an anti-TNF agent (ADA), and
monotherapy with MTX. At the end of Year 2, combination
treatment with ADA+MTX led to significantly better clini-
cal responses, physical functioning, and radiographic inhibi-
tion than either ADA alone or MTX alone11.
This report presents data from patients who participated
in an ongoing open-label extension study of PREMIER.
Patients completed 2 years of double-blind treatment and 3
years of open-label ADA therapy, allowing an analysis of 5
total years of treatment. We sought to determine whether
there was a sustained advantage of initial combination ther-
apy over either ADA or MTX monotherapy that could be
observed even after 3 years of equal opportunity for open-
label ADA therapy.
MATERIALS AND METHODS
Study design. For the first 2 years of PREMIER, the study was a multicen-
ter, randomized, active comparator-controlled, double-blind clinical trial.
The first patient was enrolled in January 2001. Patients were assigned to 1
of 3 treatments: MTX monotherapy (initiated at a dosage of 7.5 mg week-
ly and increased to a maximum 20 mg weekly, as tolerated), ADA
monotherapy (40 mg subcutaneously every other week), or combination
therapy with ADA+MTX. Efficacy and safety methods and results from the
double-blind period have been reported11. At Year 2, all patients who were
still on blinded therapy were permitted to enter the open-label phase; these
patients were switched to open-label ADA monotherapy (40 mg subcuta-
neously every other week). Blinded MTX and placebo were discontinued,
but open-label MTX (at any dosage, with a maximum of 20 mg weekly)
could be added at any time after the start of the open-label period, based on
investigator’s clinical judgment.
Patients. The PREMIER inclusion and exclusion criteria have been
described in detail11. The main inclusion criteria were as follows: ≥ 18
years of age; American College of Rheumatology (ACR) rating scale 1987
revised classification criteria for RA12 with disease duration < 3 years;
swollen joint count ≥ 8, tender joint count ≥ 10, erythrocyte sedimentation
rate ≥ 28 mm/h or C-reactive protein concentration ≥ 1.5 mg/dl, and ≥ 1
joint erosion or rheumatoid factor positivity. All patients were naive to
MTX therapy at study entry.
All patients who had at least 1 dose of open-label ADA were included
in analyses of concomitant MTX use and serious adverse events (SAE) dur-
ing the open-label period. All patients with data available for each time-
point were included in the efficacy analyses for ACR response, Disease
Activity Score 28-joint count (DAS28) remission, and Health Assessment
Questionnaire (HAQ) scores over time. For radiographic analyses and the
analysis of comprehensive disease remission, only patients in the 5-year
completers cohort were included. The 5-year completers cohort was
defined as patients with available ACR response scores and changes in
modified total Sharp scores (mTSS) at Year 5.
Efficacy and safety measures. Clinical signs and symptoms were measured
by 70% and 90% improvement in the ACR response criteria (ACR70 and
ACR90, respectively) and DAS2813. Patients were considered to have
achieved clinical remission if they achieved DAS28 < 2.6. Physical func-
tion was measured by the HAQ14.
To measure radiographic progression in patients who completed and
had radiographs at Year 5, 2 readers who were blinded to patient and
sequence evaluated each radiograph. Radiographs at baseline and Years 2,
3, and 5 were all evaluated at the same reading session using the modified
total Sharp score (mTSS; range 0–398), as described5. Changes from base-
line mTSS, joint erosion, and joint space narrowing (JSN) scores were cal-
culated at Years 2, 3, and 5.
The percentage of patients who achieved comprehensive disease remis-
sion was also determined, as measured by concurrent presence of the fol-
lowing triple criteria: clinical remission (DAS28 < 2.6), normal physical
function (HAQ ≤ 0.5), and radiographic nonprogression (change from
baseline mTSS ≤ 0.5).
Safety was assessed by evaluation of SAE of interest reported during
the open-label period of the trial.
Statistical methods. Efficacy analyses used observed data. Descriptive
analyses were performed on all efficacy variables by the originally assigned
treatment group. Percentages of patients achieving ACR responses and
mean changes from baseline radiographic scores are reported at all assess-
ment points using the original study baseline values as reference points.
The potential effects of concomitant MTX use during the open-label
period on efficacy were evaluated by using a generalized estimating equa-
tion (GEE) repeated-measures logistic model on ACR50 responses, DAS28
remission rates, and HAQ ≤ 0.05 at any time during the open-label period
(Years 3–5). Concomitant MTX use was defined as ≥ 12 weeks of contin-
uous MTX use, which was considered to be sufficient time for a therapeu-
tic trial of MTX15. Given the complex nature of MTX use in the open-label
period, modeling-based averaging was done to avoid the confounding fac-
tors in an analysis that simply compares outcome variables before MTX
initiation and at a fixed timepoint after start of MTX.
RESULTS
Disposition and patient flow. A total of 799 patients were
enrolled in PREMIER (ADA+MTX, n = 268; ADA, n =
274; MTX, n = 257). Of these, 497 patients had at least 1
dose of ADA in the open-label period (ADA+MTX, n = 183;
ADA, n = 159; MTX, n = 155). During the open-label peri-
od, 109 patients discontinued the study. Reasons for discon-
tinuation included the following (ADA+MTX, ADA, MTX,
respectively): adverse events (14.2%, 10.7%, 7.7%), with-
drew consent (8.2%, 6.9%, 7.7%), lack of efficacy (3.3%,
1.9%, 7.1%), and death (1.1%, 0.6%, 0.6%). Patients may
have had more than 1 reason for discontinuation. Of the 388
patients who completed 5 years of the study (according to
original randomized treatment group: ADA+MTX, n = 135;
ADA, n = 126; MTX, n = 127), 354 were included in the
5-year completers cohort (ADA+MTX, n = 124; ADA, n =
115; MTX, n = 115).
Baseline characteristics. Baseline disease characteristics in
the 5-year completers cohort were similar to those of the full
randomized study population, except that radiographic
scores were generally numerically lower in the 5-year com-
pleters cohort (Table 1).
Use of MTX during open-label treatment. Overall, the orig-
inal treatment arms had similar percentages of patients who
received MTX and similar numbers of weeks of exposure to
MTX during the open-label period (Figure 1). The median
numbers of weeks from the start of the open-label period to
the addition of MTX were 18 (ADA+MTX), 25 (ADA), and
12 (MTX) weeks. The percentages of patients in each treat-
ment arm who received at least 12 consecutive weeks of
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MTX during the open-label period were 42% (ADA+MTX),
50% (ADA), and 38% (MTX). Approximately 90% of those
who had at least 12 weeks of continuous MTX use had 24
weeks of MTX use. The mean weekly dosages of MTX for
these patients were similar between original treatment arms
(ADA+MTX, 14.9 mg; ADA, 14.7 mg; and MTX, 14.3 mg).
To determine whether disease activity triggered the addi-
tion of MTX during the open-label period, we calculated the
mean DAS28 score at the visit during which MTX was
restarted for each of the original randomized treatment
groups. The means were similar for each of the groups:
ADA+MTX 3.26 (95% CI 2.94, 3.57); ADA 3.63 (95% CI
3.26, 4.01); and MTX 3.65 (95% CI 3.32, 3.98).
We analyzed Year 5 data according to the original ran-
domized treatment groups without differentiating between
those who were receiving concurrent MTX therapy and
those who were not during the open-label period. A GEE
repeated-measures logistic regression model was employed
to determine whether there was a relationship between con-
comitant MTX use (≥ 12 weeks of continuous use) and
ACR50 response at any time during Years 3 to 5, with
adjustment for double-blind treatment arm. In the initial
model with all 3 original treatment groups, the ADA and
MTX monotherapy arms did not demonstrate any statisti-
cally significant difference. Therefore, the 2 original
monotherapy groups were combined in the final model,
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Table 1. Baseline disease characteristics in the randomized and 5-year completers cohorts. Statistics are group
means except where noted.
5-Year Completers Cohort by
Randomized Cohort* Original Randomization Arm
ADA+MTX, ADA, MTX, ADA+MTX, ADA, MTX,
Characteristic n = 268 n = 274 n = 257 n = 124 n = 115 n = 115
RA duration, yrs 0.7 0.7 0.8 0.8 0.7 0.8
SJC (66) 21.1 21.8 22.1 21.1 21.0 22.9
TJC (68) 30.7 31.8 32.3 30.7 32.8 31.6
DAS28 6.3 6.4 6.3 6.3 6.3 6.2
HAQ 1.5 1.6 1.5 1.4 1.6 1.5
CRP, mg/dl 3.9 4.1 4.0 3.9 3.7 3.7
mTSS 18.1 18.8 21.9 15.5 16.8 19.5
JE 11.0 11.3 13.6 9.4 9.7 10.7
JSN 7.1 7.5 8.2 6.1 7.1 8.8
Estimated annual mTSS progression,
median† 28.5 29.6 25.6 24.0 23.9 21.9
* Data from Breedveld, et al11 except for “estimated annual mTSS progression.” † Median of the estimated indi-
vidual patient annual mTSS progression. ADA: adalimumab; DAS28: 28-joint Disease Activity Score; HAQ:
Health Assessment Questionnaire; JE: joint erosions; JSN: joint space narrowing; mTSS: modified total Sharp
score; MTX: methotrexate; SJC: swollen joint count; TJC: tender joint count.
Figure 1. Patient distribution by minimum number of weeks of methotrexate (MTX) therapy received during
open-label adalimumab (ADA) treatment.
essentially for adjustment for combination treatment versus
monotherapy in the open-label period. Overall, ACR50
responses by the GEE model were similar for patients with
and without concomitant MTX use during the open-label
period. This was true for both the randomized monotherapy
groups (with MTX, 68%; without MTX, 70%) and the ran-
domized ADA+MTX group (with MTX, 77%; without
MTX, 79%). Results of a similar GEE model on DAS28
remission data were consistent with the results from the
ACR50 response data for both the monotherapy group (with
MTX, 50%; without MTX, 49%) and the ADA+MTX group
(with MTX, 65%; without MTX, 63%). The same GEE
model applied for HAQ ≤ 0.5 resulted in a statistically sig-
nificant difference for both the monotherapy group (with
MTX, 52%; without MTX, 58%) and the ADA+MTX group
(with MTX, 66%; without MTX, 71%). However, these
results still demonstrate that the addition of MTX does not
increase the likelihood of achieving HAQ ≤ 0.5 as the per-
centages were lower for the group who received MTX than
for those who did not.
Efficacy. Clinical response measures. Figure 2 presents the
percentages of patients with DAS28 remission and ACR70
and ACR90 responses over time for each original treatment
arm, based on the numbers of patients with data available at
each timepoint. At Year 5, ACR70 response was achieved by
64% of the combination therapy group, 53% of the ADA
group, and 57% of the MTX group. DAS28 remission at
Year 5 was achieved by 61% of the combination therapy
group, 52% of the ADA group, and 56% of the MTX group.
The overall pattern during the open-label period (Years 3–5)
was one of superior response for patients in the initial com-
bination therapy arm, although the differences between
treatment arms decreased by Year 5.
Physical function. Mean HAQ decreased for all 3 treatment
arms during the double-blind treatment period (Figure 3),
and improvements were sustained through Year 5. However,
patients in the original ADA+MTX arm continued to have
the lowest mean HAQ (best functional status) at each
assessment point throughout both the double-blind and
open-label periods.
Radiographic measures. Mean changes in mTSS, joint ero-
sion, and JSN scores from baseline to Years 2, 3, and 5 for
the 5-year completers cohort are presented in Figure 4. Better
inhibition of radiographic progression occurred in the initial
combination therapy group than in either monotherapy
group. At Year 5, mean change from baseline mTSS score
was least in the combination therapy group (2.9), compared
with the ADA (8.7) and MTX (9.7) monotherapy groups. In
the ADA+MTX group, 53% of patients had no radiographic
progression at Year 5, compared with only 34% and 33% in
the ADA monotherapy and MTX monotherapy groups,
respectively. Joint erosion and JSN scores demonstrated a
similar pattern of less progression in the combination thera-
py group than in either monotherapy group.
The patients included in the completers cohort who start-
ed on either MTX or ADA monotherapy had similar radio-
graphic changes at Year 2 and Year 5. In the published PRE-
MIER results from the 2-year double-blind period11, how-
ever, the MTX monotherapy group had greater progression
than the ADA group on all radiographic measures at Year 2
(represented by broken lines in the left panels of each graph
in Figure 4). Analysis of Year 2 radiographic scores for the
subset of patients who were not included in the 5-year com-
pleters cohort (i.e., patients who had Year 2 radiographs but
not Year 5 radiographs) indicated that patients in the MTX
group who were not included had numerically worse pro-
gression than did patients from the ADA group who were
not included [mean change in mTSS at Year 2 for ADA was
4.8 (95% CI 0.3, 9.3; n = 41) and for MTX was 7.2 (95% CI
3.1, 11.2; n = 39)].
Comprehensive disease remission (triple criteria). Figure 5
presents the percentage of patients in the 5-year completers
cohort with data available who achieved comprehensive dis-
ease remission according to the triple criteria [clinical
remission (DAS28 < 2.6), normal function (HAQ ≤ 0.5),
and radiographic nonprogression (change in mTSS ≤ 0.5)].
When DAS28 remission at Year 5 was used as the sole
measure of effectiveness, this was achieved by 60% of the
ADA+MTX group, 52% of the ADA group, and 57% of the
MTX group in the 5-year completers cohort. The differences
in efficacy results between the 3 original treatment groups
were more marked when the concurrent presence of DAS28
remission and radiographic nonprogression was required.
More patients in the combination therapy group (35%) than
in either monotherapy group (ADA, 13%; MTX, 14%)
achieved comprehensive disease remission according to the
triple criteria.
Safety. During the open-label period, 497 patients received
at least 1 dose of ADA, representing a total of 1,335.2
patient-years (PY). Serious infections occurred at the rate of
3.3 events per 100 PY. There were 2 cases of tuberculosis
(TB) reported (rate of 0.1/100 PY) — a case of disseminat-
ed TB in a 49-year-old woman from the US with a history
of TB as a child and unknown treatment history who was
PPD-positive and received 6 months of isoniazid prophy-
laxis during the study; and a case of gastrointestinal TB in a
78-year-old man from France. Both TB cases were previ-
ously randomized to the ADA+MTX arm. No SAE cases of
opportunistic infections occurred. One SAE case each of
lymphoma (< 0.1/100 PY) and nonmelanoma skin cancer (<
0.1/100 PY) occurred. The rate for malignancies other than
lymphomas and nonmelanoma skin cancer that were report-
ed as SAE by the investigators was 0.8/100 PY. This rate
represents 11 reported cases of malignancies — 3 cases of
breast cancer, 2 cases of bladder cancer, and 1 case each of
malignant melanoma, tongue neoplasm, pancreatic neo-
plasm, and lung, gastric and colon cancers. There were no
SAE cases of lupus-like syndrome or demyelinating disease.
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Figure 2. Percentages of patients demonstrating 28-joint Disease Activity Score (DAS28) remission
(A), 70% improvement in the American College of Rheumatology rating scale response criteria
(ACR70) (B), and ACR90 (C) during the open-label period. Includes all patients with nonmissing
data at each timepoint.
DISCUSSION
Although the benefit of combination therapy with a TNF
antagonist plus MTX has been established in early RA, there
is a need to understand the longterm outcomes of this thera-
peutic strategy11,16,17. The design of PREMIER has several
characteristics that make it unique and important for the
evaluation of therapeutic options and longterm outcomes in
the treatment of early RA. The study will ultimately follow
patients for 10 years to collect both radiographic and clini-
cal measures throughout the extended treatment period for
patients with early RA. We were able to evaluate the inter-
im 5-year data by the 3 aspects of disease control in RA
therapy: clinical remission, inhibition of radiographic pro-
gression, and physical function.
Of the original 799 patients randomized in the 2-year
blinded portion of PREMIER, 49% completed 5 years in the
clinical trial (2 years of blinded therapy plus 3 years in the
open-label extension portion of the trial). In the current
5-year analysis, patients who received initial combination
therapy for 2 years experienced better comprehensive dis-
ease control over 5 years than patients who received initial
therapy with either MTX or ADA alone. The advantage of
receiving combination therapy during the first 2 years of
treatment was discernible throughout the open-label period,
although all 3 treatment groups received the same
open-label ADA therapy (with variable MTX use) during
Years 3 to 5. The results indicate a window of opportunity to
influence the disease course with early, aggressive treatment
and suggest that there are consequences associated with
delay of combination treatment in patients whose disease
activity warrants such therapy.
How to define remission in RA has been a topic of
debate18. Our operational definition of comprehensive dis-
ease remission included a set of criteria addressing each of
the treatment goals for RA. At Year 5 of PREMIER, the
combination therapy arm had only a minimal advantage
over the monotherapy arms on the single measure of DAS28
clinical remission. When normal function was added to
DAS28 clinical remission for a combined outcome measure,
the difference between the combination group and either
monotherapy group was slightly amplified. However, when
normal function and/or radiographic nonprogression were
also considered, more than twice as many patients had com-
prehensive disease remission in the combination therapy
group than the monotherapy groups. Based on these obser-
vations, it appears that marked differences in longterm out-
comes, even in early RA, were largely due to measures that
identify the cumulative consequences of disease activity
over time — radiographic progression and, to a lesser
degree, impaired physical function. Given the proven effi-
cacy of biologic therapy in RA, it is no longer sufficient to
aim only for clinical remission. The data presented here pro-
vide insight into what can now be considered an achievable
management goal in the treatment of early RA: clinical
remission, radiographic nonprogression, and normal
function.
The importance of assessing both clinical and radio-
graphic outcomes when monitoring treatment for RA over
long periods cannot be overemphasized. Measures of
inflammation and joint damage may be dissociated19, and
radiographic progression may still occur during periods of
low disease activity, as reported with MTX monotherapy20.
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Figure 3.Mean Health Assessment Questionnaire (HAQ) scores during randomized and open-label adalimumab
(ADA) treatment. Includes all patients with nonmissing data at each timepoint. MTX: methotrexate; RCT: ran-
domized controlled trial.
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Figure 4. Radiographic scores from baseline to Year 5. Broken lines represent the full randomized
study population. Solid lines represent the 5-year completers cohort. A, B, and C present results for
modified total Sharp score (mTSS), joint erosion (JE), and joint space narrowing (JSN), respective-
ly. ADA: adalimumab; MTX: methotrexate; RCT: randomized controlled trial.
Disease activity measures (e.g., DAS28) and clinical
response measures (e.g., ACR response criteria) primarily
reflect the current status of the disease in terms of inflam-
mation and the effectiveness of therapy at a specific point in
time. These outcome measures do not necessarily identify
the consequences of prior therapy on disease progression.
On the other hand, structural damage (as captured by radio-
graphic progression) and changes in function (measured by
the HAQ) are affected by the history of disease management
and control and are more likely to reflect irreversible
damage21.
During the PREMIER open-label period, MTX could be
added to open-label ADA at the investigators’ discretion.
Almost half of the patients who entered the open-label peri-
od received MTX for 12 or more consecutive weeks. The
mean DAS28 scores prior to starting MTX in the open-label
period were just slightly greater than the cutoff value for low
disease activity (3.2) and suggest that either (1) investigators
had a lower threshold for initiating combination therapy in
patients who had already undergone 2 years of therapy in the
double-blind period, some of whom were likely to have had
good clinical response when they entered the open-label
period; or (2) investigators were making clinical manage-
ment decisions based on the growing evidence of therapeu-
tic benefit with combination therapy5,6,7,11,16. Both scenar-
ios are indicative of the higher expectations physicians have
for disease control in RA with the unprecedented efficacy of
biologic therapies. However, patients who were treated with
concomitant MTX during the open-label period did not have
notably better ACR50 responses or DAS28 remission rates
in the GEE analysis than those who did not receive MTX
during the open-label period. What made a difference in the
longterm outcomes at Year 5 was the treatment effect during
the initial 2-year, double-blind period of the study.
The efficacy and safety data in this analysis of 5 years of
treatment in PREMIER suggest a favorable benefit-risk pro-
file for use of ADA in the early RA population. Overall,
rates of SAE during Years 3 to 5 in the open-label period
were similar to or numerically lower than those reported
previously in ADA RA clinical trials22.
There are several limitations of this study. As with all
open-label extension studies, there are challenges in pre-
senting these longterm data correctly. On one hand,
longterm data are warranted because of the chronicity of the
disease. On the other hand, longterm data are hampered by
selective dropout, and data are available only for those
patients still followed in the study. Therefore, data are based
on a group of patients that is smaller than the original ran-
domized population. There is most likely an “enrichment”
of patients doing well, as those who remain in the study tend
to do better than those who drop out. Nevertheless, data
analyses such as this 5-year PREMIER report offer an
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Figure 5. Percentages of patients in the 5-year completers cohort with nonmissing data who met triple criteria for comprehen-
sive disease remission at Year 5. ADA: adalimumab; DAS28: 28-joint Disease Activity Score; HAQ: Health Assessment
Questionnaire; mTSS: modified total Sharp score; MTX: methotrexate.
opportunity to observe the longterm efficacy and safety of
treatment in patients who are monitored regularly within the
context of a clinical trial. Although the clinical and safety
results might be biased toward better results, as the patients
who experience clinical benefit remain in the study, the
comparison of radiographic data between treatment groups
might be less impressive through this approach. For inter-
pretation of the longterm radiographic progression data, we
also limited the analysis to the 5-year completers cohort.
Hence, Year 5 data were compared with the baseline, Year 2,
and Year 3 data from exactly the same patients, instead of
being compared with the full intention-to-treat population.
This approach might have contributed to narrowing the gap
between the 3 treatment groups in terms of radiographic out-
comes as patients with worse radiographic progression are
no longer in the study.
Another potential limitation of the study is that during
open-label ADA treatment, MTX was allowed at the discre-
tion of the investigator. Although this makes the data some-
what more difficult to interpret, the treatment conditions
were more similar to actual clinical practice, and results
from the GEE repeated-measures logistic model did not
point to a relationship between clinical efficacy and MTX
use in the open-label period.
In summary, 2 years of combination treatment with ADA
plus MTX led to better longterm outcomes than either ADA
or MTX monotherapy over 5 years of treatment in the PRE-
MIER trial. More patients in the initial combination treat-
ment group had clinical remission, inhibition of structural
damage, and normal function than in either monotherapy
group at Year 5. The longterm efficacy and safety data sug-
gest a favorable benefit-risk profile for the use of ADA over
5 years in patients with early RA.
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